Bubs Australia Secured Permanent FDA Formula Approval
Parents relying on these products will see more stable access following the recent regulatory transition.
Updated on Sept. 29, 2026 in Organic Food
Live Poll
Should the US require identical regulatory approvals for all imported and domestic infant formula products?
Bubs Australia received permanent FDA approval in September 2026 to supply three infant formula products within the United States. This decision replaces the temporary enforcement discretion that first allowed the company to enter the market in May 2022.
Why it matters
The permanent authorization eliminates the regulatory uncertainty that previously accompanied temporary import arrangements, providing families with long-term product availability. This transition offers greater stability for parents who depend on these specific formula options.
Official FDA authorization confirms the company's status as a permanent supplier following an initial entry in 2022. The company currently commands 8% of the premium natural infant formula segment and 20% of the goat-based formula segment in the US, while specific domestic manufacturing plans remain under development.
The players
Bubs Australia
An infant nutrition company based in Victoria, Australia, known for manufacturing goat and premium natural milk formula products.
FDA
The U.S. federal agency responsible for protecting public health by ensuring the safety and efficacy of food, medications, and medical products.
Canaccord Genuity
A financial services firm that provides investment research and forecasts regarding corporate performance and market trends.
The details
Bubs Australia currently ships its formula products via air freight from its manufacturing base in Victoria, Australia, to more than 10,000 retail locations across the US. To mitigate high logistics costs and non-Australian tariffs, the company is evaluating the potential to transition some production processes to facilities within the United States. This logistical shift is intended to improve operational efficiency after US operations accounted for roughly 60% of group revenue in FY26.
Timeline
May 2022 marked the company's entry into the US infant formula market.
FY2025 saw the premium natural infant formula segment grow by 44%.
FY2026 revenue for the company's US operations reached AU$65.8 million.
September 2026 brought the announcement of permanent FDA approval.
Health Landscape
This development marks a transition from the emergency regulatory environment established during the 2022 infant formula shortage toward standardized, long-term market access. It reflects a broader trend of integrating international premium and specialty formula suppliers into the domestic supply chain.
Parents who rely on these formulas should note that while supply chain stability is expected to improve, availability in local retailers like Walmart or Target remains subject to individual store inventory levels. If you have concerns about specific nutritional needs or transitioning your infant's diet, discuss your options with your pediatrician.
The takeaway
Permanent regulatory status suggests a more reliable long-term supply of these formula products for families who use them. Caregivers should focus on maintaining a consistent supply at their preferred local retailers and always consult a pediatrician before making changes to an infant's feeding plan.
Further reading
For broader context on nutritional standards and sourcing, explore the Organic Food section.
Source note: This article includes information reported by FNArena.
Live Poll
Should the US require identical regulatory approvals for all imported and domestic infant formula products?
